Basel (CH) 27 March 2019 – Lonza announced today the next stage in the evolution of its market-leading GS Xceed® expression platform with the launch of GS piggyBac™, a highly efficient gene integration technology. GS piggyBac™ is capable of inserting large DNA cargos into transcriptionally active and genetically stable areas of the genome associated with highly expressed genes.
News
NICE issues Medtech Innovation Briefing on PredictSURE IBD™ for inflammatory bowel disease prognosis
Cambridge, UK, 28 March 2019: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced that the UK's National Institute for Health and Care Excellence (NICE) has published a Medtech Innovation Briefing (MIB) on the use of PredictSURE IBD™ in the prognosis of inflammatory bowel disease.
BioIVT will contribute its assay development and validation expertise to support the consortium’s research initiatives
Westbury, NY – Mar. 25, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium.
Cambridge, UK, 25 March 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced it is collaborating with St George’s University Hospital, London, and the European Molecular Genetics Quality Network (EMQN), based within the Manchester Centre for Genomic Medicine at Saint Mary’s Hospital, to develop reference material for non-invasive prenatal testing (NIPT).
The 10th annual Babraham Investor Conference is taking place in Cambridge on 15 May 2019
Babraham 25th March 2018: Now in its 10th year, the one-day Babraham Investor Conference (BIC) will bring together like-minded investors focused on early-stage and scale-up life science and med-tech opportunities across the UK and Europe.
The AMR Centre, a body with public and private investors leading the UK’s response to the global health threat posed by antimicrobial resistance, has received a significant funding package to support the expansion of its pipeline of new drugs to treat drug-resistant infections.
The package totals £2.3m and is led by an investment from LifeArc, one of the UK’s foremost medical research charities. Other backers include Bruntwood SciTech, MGL, and the Greater Manchester and Cheshire Life Sciences Fund.
Developers of pioneering prognostic tools recognised for its innovative product development and contribution to life science discovery
Cambridge, UK, 21 March 2019: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, are delighted to have been awarded the Life Science Innovation award for product development at the annual Business Weekly awards.
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im Gesundheitswesen (BASG), the Austrian Federal Office for Safety in Health Care.
Babraham Research Campus is offering companies seeking funding the opportunity to present at its 10th investor conference
Babraham 18th March 2018: The Babraham Investor Conference (BIC) is back to bring together like-minded investors focussed on early-stage and scale-up life science and med-tech opportunities.
And now, companies seeking funding of between £250K to £20M have the opportunity to pitch to an audience of potential investors on 15 May at the Babraham Research Campus, Cambridge.
Aigenpulse Ltd., (Aigenpulse), a big data technology company which specialises in structuring, integrating and deriving meaning from large, disparate data assets in the life sciences sector, is continuing to strengthen its management team with the addition of Head of Delivery and Head of DevOps.